Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 34, Issue 7, Pages 413-423Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2013.05.003
Keywords
cyclooxygenase-2; tumorigenesis; innate immunity; epilepsy; neurotoxicity; neuroinflammation
Categories
Funding
- National Institute of Neurological Disorders and Stroke (NINDS) [K99NS082379, U01NS058158, U01NS074509, R21NS074169]
- Epilepsy Foundation
Ask authors/readers for more resources
Modulation of a specific prostanoid synthase or receptor provides therapeutic alternatives to nonsteroidal anti-inflammatory drugs (NSAIDs) for treating pathological conditions governed by cyclooxygenase-2 (COX-2 or PTGS2). Among the COX-2 downstream signaling pathways, the prostaglandin E-2 (PGE(2)) receptor EP2 subtype (PTGER2) is emerging as a crucial mediator of many physiological and pathological events. Genetic ablation strategies and recent advances in chemical biology provide tools for a better understanding of EP2 signaling. In the brain, the EP2 receptor modulates some beneficial effects, including neuroprotection, in acute models of excitotoxicity, neuroplasticity, and spatial learning via cAMP-PKA signaling. Conversely, EP2 activation accentuates chronic inflammation mainly through the cAMP Epac pathway, likely contributing to delayed neurotoxicity. EP2 receptor activation also engages beta-arrestin in a G-protein-independent pathway that promotes tumor cell growth and migration. Understanding the conditions under which multiple EP2 signaling pathways are engaged might suggest novel therapeutic strategies to target this key inflammatory prostaglandin receptor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available